Cargando…
Efficacy of intra-meibomian gland injection of the anti-VEGF agent bevacizumab for the treatment of meibomian gland dysfunction with lid-margin vascularity
PURPOSE: To investigate the efficacy of a novel treatment – intra-meibomian gland (MG) injection of the anti-VEGF agent bevacizumab – for MG dysfunction (MGD) with eyelid-margin vascularity. METHODS: A total of 26 eyes from 13 patients diagnosed with MGD and eyelid-margin vascularity were included i...
Autores principales: | Jiang, Xiaodan, Wang, Yuexin, Lv, Huibin, Liu, Yan, Zhang, Mingzhou, Li, Xuemin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5960246/ https://www.ncbi.nlm.nih.gov/pubmed/29805249 http://dx.doi.org/10.2147/DDDT.S146556 |
Ejemplares similares
-
Bevacizumab Eye Drops Vs. Intra-meibomian Gland Injection of Bevacizumab for Meibomian Gland Dysfunction-Associated Posterior Blepharitis
por: Tantipat, Chitchanok, et al.
Publicado: (2022) -
Pathogens in the Meibomian gland and conjunctival sac: microbiome of normal subjects and patients with Meibomian gland dysfunction
por: Jiang, Xiaodan, et al.
Publicado: (2018) -
Measurement of the Lid Margin Thickness in Meibomian Gland Dysfunction with Vernier Micrometer
por: Zhu, Hua-Ying, et al.
Publicado: (2021) -
Evaluation of the Safety and Effectiveness of Intense Pulsed Light in the Treatment of Meibomian Gland Dysfunction
por: Jiang, Xiaodan, et al.
Publicado: (2016) -
Compliance with Lid Hygiene in Patients with Meibomian Gland Dysfunction
por: Chuckpaiwong, Varintorn, et al.
Publicado: (2022)